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Autophagy is a degradation pathway of organelles and long lived proteins which 
becomes activated upon starvation conditions in all eukaryotes. Previous studies have 
validated the key role of the protein kinase Atg1 in the activation of autophagy; however, 
so far no targets have been described. Recently, a consensus motif for sites that are 
modified by Atg1 has been determined by in vitro kinase assays and bioinformatic 
analyses. Furthermore, the autophagy related factors Atg2, Atg9 and Atg18 have been 
proposed as putative Atg1 substrates. Here we present an approach to validate these 
observations in vivo. To do so, we used mass spectrometry and a novel protein-protein 
proximity assay and that based on stable enzymatic modifications. Our analysis showed 
that Atg9 and Atg2 are indeed substrates of Atg1. Moreover, we defined an Atg1 





Autophagie ist ein eukaryotischer Abbaumechanismus für langlebige Proteine und 
Organellen, der unter nährstoffarmen Bedingungen hochreguliert wird. Vorangehende 
Studien bestätigten bereits die Schlüsselfunktion der Atg1 Kinase in der Aktivierung von 
Autophagie. Bisher wurden allerdings noch keine Substrate von Atg1 beschrieben. Vor 
kurzem wurde eine Konsensussequenz für durch Atg1 modifizierte Peptide mittels in 
vitro Methoden definiert. Dies ermöglichte die Identifizierung von Atg2, Atg9 und Atg18 
als wahrscheinliche Substrate der Atg1 Kinase. In dieser Arbeit präsentieren wir einen 
Ansatz um diese Hypothese mit in vivo Methoden zu bestätigen. Dafür verwendeten wir 
quantitative Massenspektrometrie und einen neuen Protein-Protein Interaktionsassay, 
der auf sogenanntem „enzymatischem Tagging“ basiert. Unsere Experimente zeigen, 
dass Atg9 und Atg2 Substrate von Atg1 sind. Zusätzlich konnten wir eine auf unseren in 




Autophagy: a major degradation pathway and effective survival strategy 
Survival of a cell strongly depends on the supply of nutrients from the environment to 
provide energy and components for the maintenance of essential life processes. 
However, cells are frequently exposed to adverse conditions, such as starvation. To 
address this problem, eukaryotes have evolved different surviving strategies, one of 
which is called autophagy. Autophagy is defined as a degradation mechanism recycling 
cellular components that appear in excess and are not required for the momentary 
physiological situation. Degradation of these components makes these building blocks 
available for essential metabolic functions. Therefore, the main function of autophagy is 
the supply of amino acids under low-nutrition conditions, such as starvation and stress 
conditions. Consequently, this catabolic process is highly activated during starvation, 
but also during hypoxia, intracellular stress, exposure to high temperature, high culture 
density and hormone or growth factor deprivation [1]. In addition, autophagy is important 
for the clearance of damaged or unnecessary products from cells. Thus, autophagy is 
also active at basal levels during logarithmic growth. It is the only known mechanism for 
the degradation of long lived proteins and organelles, a property that makes autophagy 
important for the homeostasis of cellular components.  
Three major types of autophagy have been defined so far, all of which are 
essential for both, starvation conditions and cellular homeostasis: (1) chaperone 
mediated autophagy, (2) microautophagy and (3) macroautophagy. These three types 
differ in their sequestration and delivery mechanisms. In contrast to the last two types 
chaperone mediated autophagy has only been observed in higher eukaryotes. A 
chaperone forms a complex with the substrate proteins which are identified via a 
specific recognition sequence. This chaperone-substrate complex localizes to the 
lysosome, where target proteins become imported via a lysosomal membrane receptor 
called Lamp2 [2]. Because the amount of Lamp2 bound to the lysosomal membrane is 
limited, chaperone mediated autophagy is the only type of autophagy for which 
saturation has been described.  
Microautophagy is defined as the direct engulfment of substrates by the 
lysosome or the vacuole. Similar to the chaperone mediated autophagy, this process 
also involves a chaperone complex and in addition parts of the conventional machinery 
defined by the Atg proteins (see below). Different subtypes such as micropexophagy, 
piecemeal microautophagy of the nucleus and micromitophagy have been described [3].  
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The third type of autophagy, which is subject of this thesis, is called 
macroautophagy.  Macroautophagy is often and hereafter only referred to as 
autophagy. Autophagy is defined as sequestration of cytoplasmic material by double-
membrane vesicles and the subsequent degradation of the contents in the vacuole or 
the lysosome. Because this sequestration of cytoplasmic material is an unspecific 
process, the term bulk autophagy is also often used. However, selective subtypes 
macroautophagy also exist, the most prominent of which are mitophagy, pexophagy, 
reticulophagy, lipophagy and the Cvt-pathway, the latter is a special subtype of 
autophagy found in yeast [4,5].  
Mechanism of autophagy in yeast 
Autophagy is a mechanism conserved in all eukaryotes although individual variations 
have been described in different organisms. So far, most of the insights about the 
factors involved in autophagy have been gained by studying this process in the yeast 
Saccharomyces cerevisiae. Furthermore, all essential factors found in yeast have 
homologues in higher mammalians. Therefore, Saccharomyces cerevisiae is a suitable 
organism to study autophagy. 
The process of autophagy is mainly accomplished by autophagy related genes 
(ATG); so far 33 ATG genes have been identified. The core machinery, which is needed 
for the bulk autophagy as well as for selective types of autophagy, consists of 17 
proteins encoded by these autophagy related genes. The most important key regulator 
of the initial steps of autophagy is the Atg1 kinase [4].  
Autophagy can be classified in four stages: (1) the formation of a phagophore at 
the phagophore assembly site (PAS), (2) the expansion of the phagophore to sequester 
the cargo into autophagosome, (3) the fusion of the autophagosome with the vacuole or 
lysosome to release the autophagic body and (4) at last the degradation by vacuolar 





Figure 1. The actual model of autophagy. In the early stages of autophagy protein complexes like the Atg1 kinase 
complex or the Atg2-Atg18 complex localize to the PAS (Phagophore Assembly Site) to recruit other Atg proteins and 
form autophagosomes. The completed autophagosome is transported to the vacuole, where its outer membrane 
fuses with the vacuole to release the autophagic body. In the lumen the autophagic body is degraded and the 
degradation products are released into the cytosol. 
The initial stages 
The initiation of autophagy in yeast is affected by positive and negative regulators 
(reviewed by Cebollero and Reggiori, 2009) [6]. Negative regulators are the TOR (target 
of rapamycin) kinase complex 1 (TORC1) and Sch9 kinase of the nitrogen sensing and 
signaling systems, and the cAMP-dependent protein kinase A (PKA) of the glucose 
signaling systems. In contrast, the AMP dependent kinase Snf1 has been described as 
a positive regulator of autophagy. However, the details about the sensing of the 
extracellular nutrient levels by Tor are still unknown. In contrast to mammalians, two 
homologues of Tor, namely Tor1 and Tor2, have been described in yeast. Both are 
required for the assembly of TORC1 that is inhibited through rapamycin, whereas only 
Tor2 is necessary for the rapamycin insensitive TOR complex 2 (TORC2). During 
nutrient rich conditions TORC1 is thought to inhibit autophagy by direct phosphorylation 
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of Atg13. TORC1 has also been described to indirectly influence autophagy via Sch9 
and PKA. However, recent evidence suggests that PKA signaling is not influenced by 
rapamycin and therefore by TORC1 signaling (W. Reiter personal communications). 
Nevertheless, PKA and Sch9 also regulate autophagy independent of TORC1. Sch9 is 
the homologue of Akt and S6K in yeast. Details on how Sch9 inhibits autophagy are still 
not known.  
PKA responds to the availability of carbon sources. In the presence of glucose 
the GTPases Ras1 and Ras2 are activated. Subsequently, the two proteins bind to the 
adenylate cyclase Cdc35 and thereby stimulate cAMP synthesis. Elevated cAMP levels 
lead to the activation of PKA which in turn attenuates autophagy. It has been suggested 
that this inactivation is mediated by PKA dependent phosphorylation of Atg1, Atg13 and 
Atg18 [7,8]. The positive regulator Snf1 is the homologue of the mammalian AMPK, and 
Atg1 and Atg13 have been described as putative direct targets of Snf1 in yeast. 
Furthermore, the regulation of autophagy by Snf1 might also occur on a transcriptional 
level [9,10]. 
All positive and negative signaling inputs become integrated at the level of the 
key regulator kinase Atg1. Atg1 appears in two different complexes; the first complex 
includes Atg13, Atg17, Atg29 and Atg31 and is specific for autophagy (see Figure 2) 
[11-13]. During nutrient rich conditions Atg13 is hyperphosphorylated, which leads to a 
low binding affinity for Atg1. Upon activation the phosphorylation pattern of Atg13 
becomes altered which allows association with Atg1 and Atg17 and thereby promoting 
Atg1 activation. The assembly of the complex is important for its localization to the PAS 
where the Atg1 kinase can execute its activity. [5,11,14]. 
A second important complex including the phosphatidylinositol 3-kinase Vps34 is 
required for the expansion of the phagophore and the completion of the 
autophagosome. Vps34 is required for the recruitment of phosphatidylinositol 3-
phosphat (PtdIns(3)P) binding proteins to the PAS. Vps34 is the only 
phosphatidylinositol 3-kinase in yeast and consequently this kinase can be found in two 
different complexes, one specific for endosomal protein sorting and one for autophagy. 
The autophagy specific complex consists of Vps15, Vps34, Atg6 and Atg14. Vps15 is 
necessary for association of the complex to the membrane and Atg14 determines the 
specificity for autophagy. Once the complex is assembled it localizes to the PAS, where 
Vps34 phosphorylates the phagophore. As a consequence PtdIns(3)P binding proteins 
like Atg18, Atg20, Atg21 and Atg24 become recruited. Of these PtdIns(3)P binding 
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proteins only Atg18 is essential for the autophagosome formation [15]. Atg18 forms a 
complex with Atg2 and its PtdIns(3)P binding ability is needed for the localization of 
Atg2 to the PAS. However, the exact function of this complex remains subject to further 
investigations [16]. 
A very important and frequently discussed question concerning the initial steps of 
autophagy asks about the origin of the autophagic membranes. So far the origin itself 
has not been identified yet. Nevertheless, many studies have shown the importance of 
Atg9 for the delivery of the membrane components to the PAS. Atg9 is the only 
indispensable transmembrane protein during initiation of autophagy and the only one 
which is conserved across species [17]. Atg9 cycles to and from the PAS and this 
cycling is essential for the phagophore formation. In atg1∆, atg2∆ or atg18∆ single 
deletion strains Atg9 accumulates and remains at the PAS, which consequently leads to 
defective autophagy. Moreover, Atg9 and Atg1 are individually recruited to the PAS and 
thereby initiate the recruitment of the Atg18-Atg2 complex. Taken together the deletion 
of atg1∆, atg2∆ or atg18∆, which causes a defect in autophagy, indicates the 
importance of the retrograde transport (from PAS to its peripheral localization sites) of 
Atg9 [18].  
Two ubiquitin like proteins (Ubl) are involved in the completion of the 
autophagosome, namely Atg8 and Atg12.  Both are believed to be involved in the 
membrane expansion of the phagophore [19]. Atg8 binds to the 
phosphatidylethanolamine (PE) of the autophagic membranes [5]. In course of that the 
C-terminus of Atg8 has to be cleaved by the protease Atg4 [20], allowing Atg8 to bind to 
PE with the help of E1-like activating enzyme Atg7 and E2-like conjugating enzyme 
Atg3 [21]. Similarly, the Ubl protein Atg12 forms with Atg5 an E3 like conjugate through 
the help of Atg7 [22] and the E2 like enzyme Atg10 [23]. Subsequently, Atg16, which is 
necessary for the localization of this complex to the outer autophagic membranes, 
associates with Atg5 [24]. The Atg12-Atg5-Atg16 complex is also involved in the 
conjugation of Atg8 to PE [25]. The recruitment of the two ubiquitin like proteins  is 
dependent on Atg9 and the Vps34 complex [19]. 
The late stages of autophagy 
The targeting of autophagosome to the vacuole and its subsequent fusion 
requires for the following factors: target SNAP receptor (t-SNARE) Vam3, the vesicle 
SNAP receptor (v-SNARE) Vti, the GTPase Ypt7 and ATPase Sec18, a protein from the 
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secretory pathway [26-29]. The detailed course of events is to date only poorly 
understood. However, autophagy is known to utilize the general vesicle trafficking 
machinery, although the system is modulated differently for the use of autophagy [30]. 
The last stages of autophagy, the vesicle breakdown and release of the 
autophagic degradation product, are also not understood in detail. To date only one 
lipase for the breakdown of the autophagic body, namely Atg15, has been identified 
[31]. Furthermore, Atg22, a leucin effluxer, is the only proof of a permease for the 
transport of degradation products into the cytosol [32]. 
Cvt-pathway 
The cytoplasm to vacuole targeting (Cvt)-pathway is a special subtype of autophagy 
that is only found in yeast. The Cvt-pathway sequesters vacuolar hydrolases that are 
not derived from the secretory pathway like ApeI (aminopeptidaseI) and AmsI (α-
mannosidase). Via Cvt-vesicles these hydrolases are transported to the vacuole where 
these enzymes become activated via proteolytic cleavage [4,33,34]. Other recently 
discovered cargos are Ape4 (aspartyl aminopeptidase) and Lap3 [35,36]. 
Although, the main function of the Cvt pathway is not the degradation of proteins 
it is considered to be a subtype of autophagy since the same machinery is involved. The 
Cvt pathway is active even under nutrient rich conditions. During starvation the 
machinery switches to autophagy. Of all 33 known Atg proteins 16 are employed by the 
Cvt-pathway to determine its specificity and 17 are used by both bulk autophagy and 
the Cvt-pathway. For example, Atg1 appears in two different complexes [4]. These two 
different Atg1 complexes are important for the switch of the Cvt-pathway during nutrient 
rich conditions to autophagy during starvation conditions which is mediated via the 
TORC1 complex. The core compounds of these complexes, consisting of Atg1 and 
Atg13, are the same for autophagy and the Cvt-pathway but additional factors like 
Atg11, Atg20 and Atg24 are required to specify this complex for the Cvt-pathway (see 
Figure 2) [11,37]. However, the main difference of the Cvt-pathway to autophagy is the 




Figure  2. The different composition of the Atg1 complex in autophagy and the Cvt-pathway. This figure shows the important 
factors involved in the assembly of the active kinase complexes (factors that are not needed for the Cvt-pathway or autophagy are 
not shown). The active Atg1 kinase complex differs between autophagy and the Cvt-pathway in its constituting proteins and 
phosphorylation state. 
Atg1 kinase complex 
Atg1 is a serine/threonine protein kinase [38] and has been described as key regulator 
of autophagy. As mentioned above, Atg1 becomes activated by binding of Atg13 in 
response to starvation conditions or rapamycin treatment. This association with Atg13 
leads to the additional interaction of Atg1 with Atg17 [11], which consists as a ternary 
complex with Atg29 and Atg31. Atg29 and Atg31 are responsible for the PAS 
localization of the Atg1 kinase complex, a necessary event for the recruitment of other 
Atg proteins and the formation of autophagic membranes. Nevertheless, it has been 
reported that Atg1 kinase activity itself is not connected to PAS localization of the 
complex or the reception of the nutrient signal. If this is true the kinase activity would be 








   Figure 3. Atg1 phosphorylation sites. The activation loop is marked in orange. Phosphorylation sites 
upregulated after treatment with rapamycin are shown in red, downregulated sites are shown in blue. 
(Figure taken from Kijanska et al.) [39].  
 
Atg1 is a 101,7 kDa protein containing a domain for interaction with Atg13 on the C-
terminal half and an activation loop between DFG (aspartate-phenylalanine-glycine) and 
APE (alanine-proline-glutamate) motifs in the kinase domain at the N-terminal half (see 
Figure3). In Saccharomyces cerevisiae several post translational modifications on Atg1 
have been reported [39,40]. Importantly, these studies showed that T226 and S230 of 
the activation loop become phosphorylated upon starvation conditions or rapamycin 
treatment and this dual phosphorylation is important for the activation of the kinase. 
Both residues, T226 and S230, are highly conserved between activation loops of all 
Atg1 homologues. Furthermore, Yeh et al. reported that T226 becomes modified by 
autophosphorylation. However, it is still unclear whether this autophosphorylation event 
becomes activated in cis or trans. The importance of these sites for the activity of the 
kinase was confirmed via point mutations, which resulted in defective ApeI processing 
and defective Atg8-GFP accumulation in the vacuole. Furthermore, phosphorylation at 
these two sites enhances the Atg1 kinase activity but are not important for the assembly 
of the Atg1 complex or the PAS localization [39]. Additionally, Kijanska et al. identified 
additional rapamycin regulated sites (S351, S356, S533 and S474) on Atg1and 
confirmed the in vivo phosphorylation of two postulated PKA sites (S505 and S515) by 
quantitative mass spectrometry. However, the function of these phosphorylations still 
remains elusive. 
Atg9 
Atg9 is the only transmembrane protein that is essential for autophagy. Its function is 
supposed to be the delivery of membrane components to the forming autophagosome 
[4]. He et al. showed that Atg9 is able to interact with itself, and that this interaction is 
necessary for the anterograde (from cytosol to PAS) transport of Atg9 [41]. In 
logarithmic growing conditions Atg9 is found in punctate structures throughout the 
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cytosol. In autophagic conditions Atg9 starts to cycle to the PAS, which is essential for 
membrane formation [18]. Many microscope studies showed that the majority of the 
Atg9 containing puncta colocalize with mitochondria [42,43]. However, these puncta 
near the mitochondria are independent clusters [43]. Indeed, the origin of the 
membranes is still debated and the possibility that Atg9 comes from the Golgi-
endosomal system still exists [44]. While the Atg9 transport to the PAS in the Cvt-
pathway depends on Atg11 and the actin cytoskeleton [45], the anterograde transport 
during autophagy is supported by the peripheral membrane protein Atg23 and the 
transmembrane protein Atg27 [46,47]. Nevertheless, Atg23 and Atg27 only influence 
the efficiency of the process [48]. 
Furthermore, as already mentioned above, the retrograde transport of Atg9 
depends on the PAS localization of the Atg13- Atg1complex, the Vps34 complex, the 
Atg2-Atg18 complex as well as on the binding ability of the Atg2-Atg18 complex to Atg9 
[18,49]. 
Atg2 – Atg18 complex 
After induction of autophagy Atg2 and Atg18 form a complex. Atg18 possesses a 
PtdIns(3)P binding motif consisting of FRRG (phenylalanine, arginine, arginine, glycine) 
and thereby the Atg2-Agt18 is recruited to the phagophore via the Vps34 complex, 
which specifically phosphorylated the phosphoinositides of the autophagic membranes 
[16]. Furthermore, Atg18 can also bind PtdIns(3,5)P2, but it was suggested that this 
feature is not important for autophagy [50]. Moreover, Obara et al. bypassed the 
requirement of Atg18 for PAS localization of Atg2 by adding a 2xFYVE (phenylalanine, 
tyrosine, valine, glutamine) domain (a specific PtdIns(3) binding domain) directly to 
Atg2. However, cells containing Atg2 with this PtdIns(3)P binding motif were still unable 
to overcome their defect in autophagy. Therefore, Obara et al. proposed that, besides 
the localization of the Atg2-Atg18 complex, Atg18 has an additional role in autophagy 
[16].  
However, speculations about the involvement of the Atg2-Atg18 complex in the 
retrograde transport of Atg9, the generation of the negative curvature of the 
phagophore, the construction and maintenance of the elongating edges of the 
expanding membrane [16] or a role for Atg8 protection from unregulated cleavage by 
Atg4 [51] still need to be proven.  
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Atg2 is a poorly characterized protein. Deletion studies performed by Reggiori et 
al. show that Atg2 is essential for autophagy and further propose a role of Atg2 in the 
retrograde transport of Atg9 [18]. The Atg2 recruitment to the PAS by Atg18 and 
subsequently its function is disturbed in Atg1, Atg6, Atg9 and Atg14 deficient cells [52]. 
Nevertheless, the exact role of Atg2 needs to be determined.  
Comparison of mammalian autophagy to yeast 
As described above many autophagy related factors are highly conserved 
between eukaryotes. Therefore, many similarities in the mechanism of autophagy 
between mammalians and yeast can be expected. However, autophagy in mammalians 
still remains a poorly characterized subject; therefore this chapter shall only give an 
overview about the similarities and differences to yeast (as far as examined). 
For instance, autophagy in mammalian organsims is also regulated by AMPK 
and mTORC1 signaling. Mammalians have two Atg1 kinase homologues, Ulk1 and 
Ulk2, but only Ulk1 is essential for autophagy [53-55]. During starvation the AMPK 
kinase phosphorylates Ulk1 on S317 and S777, thereby leading to the initiation of 
autophagy. During adequate nutrition conditions mTORC1 phosphorylates S757 of 
Ulk1, which leads to interference for the interaction of AMPK with Ulk1 and causes the 
inhibition of autophagy [56].  
The enhancement of the Ulk1 kinase activity, as well as the localization of Ulk1 to 
the phagophore requires the formation of the Ulk1 kinase complex harboring two other 
proteins, mAtg13 and Fip200, the respective homologues of Atg13 and Atg17 in 
Saccharomyces cerevisiae [57,58]. In contrast to yeast, phagophore formation takes 
place at multiple sites in the cytoplasm [30]. Furthermore, regulation of mAtg13 by 
mTORC1 has also been described in the mammalian system. Though, unlike the 
situation in yeast, the complex of mAtg13 and Ulk1 is not only found during starvation, 
these two proteins also interact during rich growth conditions [57,58].  
Another essential factor of this complex is the mAtg13 binding protein Atg101, 
which is thought to protect mAtg13 from proteasomal degradation [57,58]. 
Recruitment of PtdIns(3)P binding proteins to the PtdIns(3)P on the autophagic 
membranes requires the activity of Vps34. As in yeast two different PtdIns(3) kinase 
containing complexes exist, one for autophagy and one for the endosomal protein 
sorting, the  common core complex consists of Vps34, Beclin1 and Vps15. The 
specificity of this core complex for autophagy is determined by mAtg14 [59]. 
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Additionally, the PtdIns(3) kinase interacting proteins UVRAG (UV radiation resistance-
associated gene), AMBRA1 (activating molecule in beclin1-regulated autophagy) and 
Bif1 (Bax-interacting factor 1) were discovered as positive regulators for autophagy, 
whereas the interaction with rubicon (RUN domain and dysteine-rich domain containing 
beclin-1-interacting protein), and the antiapoptotic Bcl-2 family members Bcl-2 (B-cell 
lymphoma 2) and Bcl-xL (B-cell lymphoma extra large) inhibits autophagy [60].  
The PtdIns(3)P binding proteins in mammalians include Alfy (autophagy-linked 
FYVE protein), DFCP1 (double FYVE domain-containing protein) and the two Atg18 
orthologs WIPI1 and WIPI2 (WD repeat proteins interacting with phosphoinositides 1 
and 2). The function of WIPI1 and WIPI2 for mammalian autophagy is only partially 
understood and still needs to be analyzed in detail [30]. However, WIPI1 has been 
shown to interact with one of the two Atg2 orthologs but colocalizes with LC3 
(microtubule-associated protein light chain 3), a homologue of Atg8. WIPI2, which is 
thought to be the ortholog to Atg21 in mammalians, associates indirectly with Atg2a and 
may be involved in the recruitment of LC3 [61,62]. While the contribution of DFCP1 to 
autophagy is still unknown, Alfy is at least known to colocalize with Atg5 and LC3 [63]. 
As in yeast the origin of the autophagic membranes in mammalian cells remains 
unknown. However, in mammalians the cycling of mAtg9 was observed to occur 
between the trans-Golgi network, the endosomes and the LC3 labeled 
autophagosomes. MAtg9 cycling depends on ULK1 and the PtdIns(3) kinase [64]. 
Furthermore, the p38alpha MAPK (mitogen-activated protein kinase) is known to inhibit 
autophagy by regulating the interaction of p38IP and mAtg9 [17]. 
Homologues of both Ubl systems of yeast can also be found in mammalians. The 
mammalian Atg12-Atg5-Atg16L complex has a higher molecular weight than in yeast 
and the membrane targeting of Atg16L only depends on Atg5 [65]. Nevertheless, the 
complex requires the Ubl protein Atg12 for the membrane elongation [66]. Additionally, 
a recent study describes Alfy as a part of this complex [67]. The Ubl protein Atg8 has 
four homologues in mammalian, namely LC3, GABRAP (γ-aminobutyric-acid type A 
receptor associated proteins), GATE-16 (golgi-associated ATPase enhancer of 16kDa) 
and the uncharacterized Atg8L, which are believed to be involved in the completion of 
the autophagosome. The C-terminus of LC3, GABRAP and GATE-16 is removed by 
proteolytic cleavage which leads to to exposition of a glycine that allows binding to the 
PE in the autophagic membranes. In vitro studies provide evidence that the four Atg4 
homologues hAtg4A, hAtg4B, hAtg4C and hAtg4D are at least partly responsible for this 
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cleavage. Atg3 and Atg7 modify these cleaved forms into the membrane bound LC3-II, 
GABRAP-II and GATE-16-II. LC3-I is the only one that does not localize to membrane 
compartments before modification [68].  
The mechanism for the targeting of autophagosomes to the lysosomes is subject 
of many recent studies. Kimura et al. observed microtubule and dynein-dynactin motor 
complex dependent the movement of autophagosomes, which is mediated by the LC3. 
This movement is supposed to be involved in the targeting of the autophagosomes, but 
whether microtubules prevent the early fusion of immature autophagosomes as 
suggested by Fass et al. or mediates their fusion by targeting the autophagosomes to 
the lysosomes as proposed by Köchl et al. is still not clear. However, microtubules were 
also found to be involved in the formation of autophagosomes but details about the 
exact function of this event remain to be examined [69-71].   
The study of Gordon and Seglen as well as the study of Dunn proposes that 
mammalian autophagosomes fuse with endosomal vesicle forming an amphisome (a 
prelysosomal hybrid organelle) before they fuse with lysosomes [72,73]. The t-SNAREs 
Vamp3 and GTPase Rab11 are required for the development of amphisomes, whereas 
the SNAREs VAMP7, VAMP8 and Vti1b as well as Rab7, which depends on the 
lysosomal membrane proteins Lamp1 and Lamp2, are required for the fusion with the 
lysosome [74-76]. These proteins were found to be involved in the fusion processes of 
autophagy but for insights into the exact mechanisms of these fusion processes and the 
role of these further studies are necessary. 
Autophagy and disease 
In the early years of autophagy its major role was supposed to be the nutrient supply 
during starvation but in the recent years connections with lots of cellular processes and 
diseases have also been reported.  
For example, autophagy plays an essential role in the development of the 
fertilized zygote to the blastocyst. To enable the development of the highly differentiated 
oocyte into an undifferentiated state after fertilization, degradation of the whole maternal 
mRNA and proteins is necessary. Tsukamoto et al. found evidence that autophagy is 
involved in this process, since autophagy deficiency is lethal for the zygote. Moreover, 
in this developmental stage autophagy seems to be important to provide sufficient 
amounts of amino acids for protein synthesis. Subsequently, in autophagy deficient cells 
the fertilized zygote could not develop to the blastocyst [77]. Furthermore, other studies 
 18 
 
described that autophagy is essential directly after birth, when trans-placental nutrition 
supply is interrupted [78].  
Autophagy was also found to be connected with neurodegenerative diseases. As 
mentioned above, a major function of autophagy is the turnover of cytoplasmic 
components to avoid the accumulation of abnormal or damaged proteins. In Atg7 and 
Atg5 deficient mice an increase of polyubiquitinated proteins in neuronal cells was 
observed. Autophagy was suggested to be involved in the degradation of these proteins 
because the proteasome function in these cells was still normal and these two 
mechanisms form the major degradation pathways of proteins in mammalians. The 
accumulation of these proteins led to behavioral defects, uncoordinated movements and 
shortened life span [79-81]. Furthermore, a connection to Huntington disease was 
observed. The cause for Huntington is the accumulation of mutant huntingtin protein in 
the cell and this accumulation has been shown to be extremely increased in neurons 
defective for autophagy [80].  
Moreover, mutations or downregulation of some ATG genes shorten the life 
expectancy in lower eukaryotes like yeast, Caenorhabditis elegans and Drosophila 
melanogaster and therefore provided a link of autophagy with aging. In aging cells the 
activity of autophagy decreases thereby leading to a lower clearance of damaged and 
wrong synthesized components, causing typically age-related phenotypes. In mouse 
liver cells the observed age-related phenotypes vanished by restoring the defects in 
autophagy. Additionally, in recent years caloric restriction, which causes higher activity 
of autophagy, was observed to mediate anti-aging effects. [82]. 
Autophagy has also been described to be involved in immunity. Autophagy 
provides cytosolic peptides for antigen presentation on MHC II molecules [83,84]. 
Furthermore, the Toll-like receptors 4 and 7 apparently can induce autophagy and lead 
to the destruction of intracellular microorganism [85,86]. Examples for autophagy 
supporting cellular defense are given by group A Streptococcus and Salmonella 
typhimurium, both of them are enveloped by autophagosomes  [87,88]. 
The role of autophagy for cancer development is still ambiguous. Mathew et al. 
discovered that autophagy protects the genome by maintaining metabolism and survival 
during metabolic stress thereby inhibiting tumor development and Liang et al. showed 
the tumor suppressing effect of the mammalian Atg6 homologue Beclin-1[89,90]. On the 
contrary Carew et al found that the effect of the anti-cancer drug SAHA is enhanced 
when autophagy was disrupted [91]. Additionally, it was found that a defect in 
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autophagy and apoptosis promotes necrotic cell death. Consequently when autophagy 
is inhibited in starvation the cell death of apoptosis-refractory tumors can be restored, 
but this necrosis correlated also with inflammation and accelerated tumor growth [92]. 
This area still requires for more intense investigations to evaluate if there is a clinical 
possibility to apply autophagy for tumor suppression. 
To sum it up, all these examples indicate the importance for further investigations 
in autophagy and illustrate the growing interest in this subject. 
Methodic issues 
Current state of the art: Atg1, Atg2, Atg9 and Atg18 
As summarized above, there remain many open questions about the mechanism of 
autophagy. Our research group together with our collaborators focused on the 
identification of targets of the Atg1 kinase. Through a peptide chip and a subsequent 
bioinformatic analysis a consensus motif for the Atg1 could be identified. The 
identification of this motif served as a basis for a scan for proteins carrying putative 
phosphorylation sites and provided the first hint for Atg2, 9 and 18 to be putative kinase 
substrates. Moreover, with an in vitro kinase assay and point mutations, our 
collaborators could confirm some of these sites [Claudine Kraft, unpublished data]. 
These data give strong evidence for the putative targets of the Atg1 kinase 
complex but since these results were obtained in vitro a validation in vivo is required. 
Thus, the aim of my master thesis is the examination of Atg2, 9 and 18 as targets of the 
Atg1 kinase in the yeast Saccharomyces cerevisiae. To do this, we use two different 
approaches: first, quantitative mass spectrometry and second, a proximity assay, which 
has been developed in our laboratory and is based on stable enzymatic modifications. 
Protein modification: Mass spectrometry 
Our mass spectrometric analysis is based on the analysis of modifications of purified 
proteins of interest. To be able to do this, we use a modified version of the HTBeaq tag 
which is the established tandem affinity purification system in our lab.  
Our HTBeaq tag is a modified version of the tag which has been developed by 
Tagwerker et al. 2006. The tag consists of three elements: two poly-histidin domains 
followed by three TEV cleavage sites and finally a biotinylation sequence. 
Nourseothricin is used as a selection marker. By using this tag two purification steps 
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can be performed. With the poly-histidin domain a rough pre-purification with Ni2+ -
Sepharosebeads can be performed followed by a more specific purification using the 
strong interaction of biotin and Streptavidin-Agarose beads [93]. 
Another important advantage of this tandem affinity purification method is that the 
procedure is done under denaturing conditions. This is of high importance since 
posttranslational modifications can be preserved [93]. 
For quantitative analysis stable isotope labeling with amino acids in cell culture 
(SILAC) labeling is our method of choice. With SILAC the differences of the proteome of 
cells under different conditions can be observed. This method is based on the principle 
that peptides, which are labeled with different stable isotopes, are chemical identical but 
differ in their mass.  
To perform a SILAC analysis a preculture of the cells has to be divided. One half 
is grown on normal full medium, the other half is supplemented with 13C labeled arginine 
and lysine. SILAC strains are auxotroph for lysine and arginine and therefore have to 
incorporate these amino acids to be able to grow. However, recent experiments [Verena 
Unterwurzacher, unpublished data] showed these auxotrophies to be not absolutely 
necessary for efficient incorporation of many amino acids. In the same environment the 
cultures incorporate these amino acids in the same amount and thus they are 
comparable. Only one of the halves becomes treated with the condition of interest (in 
our case we used rapamycin to induce autophagy) and immediately after harvesting the 
treated and untreated cells are unified. Next, the proteins are purified and prepared for 
mass spectrometry. Treatment with trypsin digests the proteins into peptides of different 
sizes, each carrying arginine or a lysine at the C-terminal end. Consequently, they are 
labeled with a heavy or light amino acid. The resulting heavy to light ratio gives 
information about relative differences in the abundant peptides. [94]. 
Protein interaction: M-track 
As described above activation of autophagy requires dynamic interaction of a variety of 
different factors. We wanted to study these protein-protein interactions using an assay 
based on enzymatic tagging. Enzymatic tagging is defined as a transfer of a chemical 
modification between protein tags that can easily be detected with an appropriate 
readout system. I made use of the so called M-track that has been developed in our 
research group, to study the binding of Atg1 to its putative targets Atg2, Atg9 and Atg18. 
For the M-track the two proteins of interest had to be tagged with either a hyperactive 
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catalytic domain of the murine histone methyltransferase (HMT) Suv39h1 (donor) or a 
region of the first 21 amino acids of histone3 containing lysine 9 (our tag contains four 
copies of this 21 amino acid region), which is a substrate of the HMT. Additionally, the 
histone tag also contains three HA-epitopes, which are used for loading control. 
Depending on the strength of the interaction, lysine 9 either becomes mono-, di- or 
trimethylated by the HMT (see Figure 3). For each of these types of modification a 
specific monoclonal antibody exists. 
 
 
Figure 3. A schematic illustration of the mechanism of the M-track. When the two proteins of interest interact the 
Acceptor becomes methylated through the Donor. Each lysine 9 of the four histone 3 tags can be mono-, di- or 
trimethylated (here only trimethylation is shown). 
 
One major advantage of enzymatic tagging is that it allows examination of interactions 
of membrane and membrane associated proteins like Atg2, Atg9 and Atg18. 
Furthermore, the method allows detection of transient interactions. Interactions can be 
observed at endogenous protein levels. Finally, quantification of the methylation signal 
is also possible. [Zuzuarregui et al., manuscript submitted (Nature), I. Dohnal and C. 
Friedmann, PhD thesis]. Once this assay is established for Atg1 proteins it will provide 
many possibilities: For example the interaction can be studied in ATG deletion mutant 
strains to assess the importance of other factors on a specific interaction. Furthermore, 
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interaction of point mutations at specific phosphorylation sites can be studied to 
examine the effects of specific signaling cascades. 
Aim of Thesis 
This thesis is based on recently published Atg1 phosphorylation studies of Kijanska et 
al. and Yeh et al. These phosphorylation analyses emphasized the key role of the Atg1 
kinase as mediator between nutritional signaling and autophagy. Lots of efforts have 
been undertaken to identify the different signaling inputs for the Atg1 kinase. Also the 
consequences of the activation of the kinase have been thoroughly studied.  However, 
the direct targets of the kinase have not been identified yet.  Our collaboration partner, 
Claudine Kraft, identified putative targets of the Atg1 kinase by in vitro methods and 
examined whether Atg1 can still phosphorylate point mutated variants of these putative 
targets by in vitro kinase assays. The aim of the thesis presented here is the validation 
of the putative Atg1 targets, Atg2, Atg9 and Atg18, by in vivo methods such as 
quantitative mass spectrometry. With this method we can identify the exact sites that 
are regulated by the kinase Atg1. A second approach focused on the establishment of 
the M-track assay, an enzymatic tagging system that was established in our laboratory 
to examine protein-protein interactions. This in vivo method will allow us to confirm that 
Atg1 directly interacts with its targets. Furthermore, by using deletion mutants that 
inactivate the Atg1 kinase complex it will allow us to study the dependency of the 


























































WR 619 BY Mat A his3∆1 leu2∆0 LYS2 met15∆0 ura3∆0 
WR 157 BY SILAC Mat A arg4::KanMX lys1::???  
yCK 481 BY Mat A atg1::HIS 
WR636 BY SILAC Mat A Atg9-HTBeaq::NatMX 
IH 59 BY SILAC Mat A Atg9-HTBeaq::NatMX atg1::HIS 
IH 159 BY Mat A Atg2-HTBeaq::NatMX 
IH 178 BY Mat A atg1::HIS Atg2-HTBeaq::NatMX 
IH 185 BY Mat A atg1::HIS Atg18-HTBeaq::NatMX 
IH 167 BY Mat A Atg18-HTBeaq::NatMX 
yCK 723 Mat A atg1::KanMX atg9::KanMX  
IH 227 Mat A atg1::HIS atg2::KanMX 
IH 299 Mat A atg1::HIS atg18::KanMX 
 
Plasmids 
IC 18 Atg1-4xH3HA YCp33 
IC 59 Atg2-linker-Suv320 YCp111 
IC 35 Atg9-Suv320 YCp111 
IC 2 Atg18-linker-Suv320 YCp111 
pCF 7 PBS2-Suv320 YCp111 
pCF 33 Sho1-4xH3HA YCp33 
pAP 108 Fps1-Suv320 YCp111 
pAP 149 Fps1 4xH3HA YCp33 
pCK 364 Atg2-TAP pRS315 
pAP 28 Suv320 YCp111 
pGA 2259 NheI KanMX 
pGA 2260 NheI His3MX 
pCF 154 Ste20-H3HA YEp 195 
pCF181 Cdc42-H3HA YEp195 




For the construction of Atg2, Atg9 and Atg18 HTBeaq tagged variants in Atg1 deficient 
strains and wild type strain the HTBeaq::NatMX1 cassette was amplified from a plasmid 
with the appropriate primers (Atg2_tag_fw, Atg2_tag_re, Atg9_tag_fw, Atg9_tag_re, 
Atg18_t_fw and Atg18_t_re) and subsequently transformed into the strains WR 619 and 
yCK 481. Except the HTBeaq::NatMX for Atg9 tagging, this cassette was transformed 
into WR 157. Furthermore, to obtain a BY SILAC Atg9-HTBeaq tagged strain with atg1∆ 
backgrounds again a His3MX6 knockout cassette was amplified with atg1_ko_fw and 
atg1_tag_re from the plasmid pGA 2260 and transformed into WR 636. 
The double deletion strains of atg2∆ or atg18∆ with atg1∆ were obtained by the 
amplification of a KanMX deletion cassette from pGA 2259 (with Atg2_ko_fw, 
Atg2_tag_re, Atg18_ko_fw and Atg18_t_re) and the transformation of this cassette into 
yCK 481. 
The deficiency for autophagy of the constructed strains was confirmed by 
defective ApeI processing. 
Plasmid construction 
The plasmid Atg1-4xH3HA has been constructed as follows: The gene including 1kb of 
the upstream sequence was amplified from a genomic prep of BY 4741 in two 
fragments. By using the primers Atg1_sphI_fw1, Atg1_bglII_re1, Atg1_bglII_fw2 
Atg1_xbaI_re2 a SphI restriction site could be added at the 5’ end and the stop codon 
could be replaced with an XbaI restriction site. Atg1 fragment 1 was digested with SphI 
and BglII and Atg1fragment 2 with BglII and XbaI. These two fragments were inserted 
into the vector pAP149 via the SphI and XbaI sites. 
Atg9 and Atg18 were cloned into pAP108 with a similar strategy. Again the genes 
including 1kb of their promoter were amplified from a genomic prep of BY 4741 and 
inserted into pAP108 via the SphI and XbaI sites. Atg18, which is a small gene, could 
be amplified at once with the primers Atg18_sphI_fw and Atg18_link_xbaI_re. Because of its 
size Atg9 was amplified in a two step manner the primers Atg9_sphI_fw1, 
Atg9_ageI_re1, Atg9_ageI_fw2, Atg9_xbaI_re2 using AgeI as restriction site for the 
ligation of these two fragments. In contrast to Atg1 and Atg9, the Atg18 primer was used 
to add a linker upstream of the XbaI site. 
                                            
1 The plasmid contains a point mutation in the TEV site therefore it cannot be used. 
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Atg2 is an extremely large gene so another cloning strategy had to be chosen. 
First Atg2 fragment 1 was amplified with Atg2_salI_fw1 and Atg2_ncoI_re1, the last two 
cycles were done with Dream Tag to directly subclone the product into pGEMT System I 
(Promega). As second step Atg2 fragment 1 was cut from pGEMT with SalI and BglII 
and an Atg2 fragment 2 of pCK364 with BglII and BamHI to subclone them via SalI and 
HindIII into pBluescript (WR EC 293). Atg2 fragment 3 was amplified from genomic DNA 
with Atg2_sacI_fw3 and Atg2_link_xba_re3 (again adding a linker). Atg2 fragment 3 
was cut with BamHI and XbaI and Atg2 fragment 1+2 with SalI and BamHI for triple 
ligation into pAP28. 
The functionality of the constructed plasmids was checked via complementation 
of the appropriate deletions strains and subsequent confirmation of ApeI processing. 
SILAC labeling 
SILAC labeling is based on a method described by Ong et al. [94] with the following 
variation: Strains carrying the protein of interest in a HTBeaq-tagged version were grown 
in media containing either 13C labeled arginine and lysine or 12C arginine and lysine until 
an OD600 of one.  
Purification of HTBeaq tagged proteins 
The established tandem affinity purification in our laboratory is based on the method of 
Tagwerker et al. [93] with the following variations: yeast cultures were grown to OD600 = 
1 and harvested by filtration via a 0,45 µm nitrocellulose membrane. In case of 
autophagy induction by rapamycin cells were treated 45 minutes prior to harvesting with 
0,2 ng rapamycin per ml culture. Directly after harvesting, the cells were quick frozen in 
liquid nitrogen. The cells were homogenized with a Freezer Mill using the following 
conditions: 10 minutes precooling then 7 cycles of 3 minutes breakage, with 3 minutes 
cooling at 15 CPS. The cells were resuspended in a denaturing Guanidium buffer (6 M 
Guanidine hydrochloride, 50 mM Tris (pH=8,8), 5 mM NaF, 0,1% TritonX-100, 1mM 
PMSF and a proteinase inhibitor cocktail (ETDA-free complete Mini)) and spun down at 
14 000 rpm for 20 minutes to get rid of the cell debris. The cell extracts were incubated 
on Ni-Sepharose beads for five hours on a rotator. Then the beads were washed two 
times with urea buffer (8M urea, 50 mM Na-PO4, 300 mM NaCl, 0,01% Tween, pH 8) 
and three times with the same urea buffer pH of 6,3 to get rid of any unspecific proteins. 
Afterwards the proteins were eluted from the beads in three washing steps with the 
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same urea buffer at pH 4,3 and additional 10mM EDTA. The pH of the 3 eluates was 
adjusted with 2 M NaCl to 8 before the eluates were incubated with streptavidin-agarose 
beads over night. The next day the beads were washed three times with a urea buffer 
containing 1% SDS (8M urea, 200mM NaCl, 100 mM Tris (pH8)) and three times with 
this urea buffer without SDS before the samples were delivered to mass spectrometry. 
Sample preparation for the M-track 
The cells were grown to the OD600 of 0,8 to 1, then the first samples were taken and the 
time course was started. At every time point the OD600 had to be measured for the latter 
calculation of the required amount of the 1x SDS sample buffer. The samples were 
spun down at 2500 rpm, 4°C for 1 minute and the cell pellets were frozen in liquid 
nitrogen. After the pellets were thawed on ice they were resuspended with 400µl of 1% 
glucose. Then 0,5 M NaOH was added in a 1:1 ratio and after 4 minutes incubation at 
room temperature the cells were spun down. The supernatant was removed and the 
pellet resuspended in 1x SDS sample buffer (amount of SDS buffer = 15xVol of 
samplexOD600). As a next step the samples were boiled for 5 minutes and spun down 
again to collect the supernatant. The protein amount was measured with the Christian-
Warburg method and 30 ng of protein were used for the SDS PAGE. 
Immunoblotting for the M-track 
The proteins were separated by SDS-PAGE and with wet transfer they were blotted 
onto a nitrocellulose membrane overnight. The blocking was done in 1% milk-PBST 
solution. Next, the blot was incubated 90 minutes with me3k9 antibody (1:500) and the 
secondary mouse antibody (1:10 000), which were dissolved in YE. For the production 
of YE 1g of homogenized wild type cells was resuspended in 10ml PBST and was spun 
down to get rid of the cell debris. Furthermore, a complete protease inhibitor cocktail 
was added to the supernatant before it was stored at 4°C. For use, this supernatant was 
diluted with the ratio of 1:5. The blot was analyzed with the ECL detection system. 
Then the blot was stripped for one minute in stripping solution (32g MgCl2.6H2O 
in 80ml H2O + 472µl acetic acid) and blocked again in 5% milk-PBST solution. The HA-
antibody (1:10 000) and mouse antibody were dissolved in 1% milk-PBST solution and 
for 90 minutes incubated with the blot. 
The mouse monoclonal me3k9 antibody as well as the HA antibody were 




As described in the introduction of this thesis, kinase Atg1 plays a key role in the 
regulation of autophagy. However, its direct in vivo targets have not yet been clearly 
identified. In vitro studies propose Atg2, Atg9 and Atg18 as putative targets of the Atg1 
kinase (Claudine Kraft, personal communications). In the work presented here, we 
wanted to validate these observations in vivo. To do so, we made use of quantitative 
mass spectrometry. Furthermore, we employed a protein proximity assay to detect 
interaction of the protein kinase with its putative targets. 
Mass spectrometric analysis of Atg9 phosphorylation sites in logarithmic 
growing cells and autophagy inducing conditions 
In vitro kinase assays suggested that Atg9 might be a target of Atg1. Also, a 
bioinformatic scan for Atg1 consensus motifs in Atg9 revealed S657, S831 and S948 as 
putative sites for Atg1 dependent phosphorylations [Claudine Kraft, personal 
communication]. Single point mutations as well as a combination of point mutations at 
all three sites lead to aberrant phenotypes in autophagic pathways.  
To confirm putative Atg1 dependent phosphorylation sites of Atg9 in vivo, we 
established a phosphomap of Atg9 during logarithmic growth as well as during 
autophagy induced conditions. To do so, we performed a tandem affinity purification of 
Atg9 via a modified version of the HTBeaq tag (Reiter et al., manuscript in preparation) 
from logarithmic growing yeast cultures, or alternatively from cultures that were treated 
with rapamycin and analyzed the modifications with mass spectrometry. 
Altogether, we detected 23 phosphorylation sites on Atg9; most of them were 
found at serines and only four at threonines. We were able to achieve a 57,8% 
sequence coverage, which is high at the N- and C-terminal ends of Atg9. For the central 
part of the protein less coverage could be achieved probably caused by hardly 
accessible transmembrane domains located between the amino acids F319 and S744. 
Accordingly, most of the discovered phosphorylations sites were also found in the N- 
and C- termini of Atg9. The N-terminus of Atg9 contains S19, S26, S55, S59, S109, 
S122, S131, S135, S143, S144, S168, T236, S250, and the C-terminus S786, S792, 
T794, S802, T804, S819, S864, S899, S948, S969 (see Figure 4). The majority of the 
phosphorylations sites on Atg9 were detected during autophagic conditions, indicating 
that this factor becomes hyperphosphorylated during these conditions.  
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With our analysis we found phosphorylations on S831 and S948, two of the sites 
that have been implicated with autophagy by in vitro studies. Both of these 
phosphorylations were only found during autophagic conditions, although this result also 
might be explained by suboptimal sequence coverage. Unfortunately, we were not able 
to detect a phosphorylation at S657, the third of the in vitro identified phosphorylation 
sites (see Figure 4). This might be due to technical problems caused by the peptide 
sequence surrounding S657: Our standard sample preparation for mass spectrometry 
involves tryptic digestion of the proteins. Trypsin cleaves after arginines and lysines. 
Close proximity of a phosphorylation site to lysines or arginines can negatively influence 
the efficiency of a cleavage, leading to so called miscleaved peptides. In the case of 
S657, such a miscleavage would lead to a 40-residue peptide, which is a size that 
would be hard to detect with mass spectrometry. To find S657 we also tried to digest 
purified Atg9 with chymotrypsin and subtilisin, admittedly without success.  
Comparison of Atg9 phosphorylation sites in Atg1 wild type and atg1∆ 
background gives first evidence for Atg1 dependent sites 
To detect Atg1 regulated sites we additionally analyzed phosphorylation patterns of 
Atg9 purified from wild type and atg1∆ cells in parallel. We achieved an overlapping 
sequence coverage of 35% from the different strain backgrounds. These overlapping 
regions covered 16 of the above described phosphorylations sites of Atg9 (see Figure 
4).  
Four of these sites, S864, S948, S969 and T804, were only found in the Atg1 
wild type background but not in the atg1∆ strain, indicating that the phosphorylations at 
these sites might be regulated by the Atg1. Phosphorylations of S864, S948 and S969 
were found in the majority of the samples purified from wild type. Therefore, it is very 
likely that these sites are dependent on Atg1 kinase. In contrast, the phosphorylation of 
T804 was only found once as ambiguously allocated. Hence, this site would require 
more experiments to be considered as a genuine Atg1 targeted site. 
Nevertheless, the possibility remains that these phosphorylation sites were just 
not selected for fragmentation in MS2/MS3 in the atg1∆ background, although they 
might be present in both backgrounds. To validate the observed phosphorylation sites 
and to determine whether the sites present in both backgrounds were regulated by Atg1 




Figure 4. Summary of all phosphorylation sites of Atg9 found in our analysis. The phosphomap in (A) provides 
an overview of all phosphorylation sites of the Atg9 protein sequence. The exact locations are depicted in (B). All 




Identification of Atg1 dependent sites in Atg9 via SILAC experiments  
For the quantitative phosphorylation analysis SILAC (stable isotope labeling with amino 
acids in cell cultures) was our method of choice. SILAC is based on supplementation of 
heavy and light amino acids to the media which leads to different labeling of proteins 
and consequently enables the simultaneous analysis of the tryptic peptide mixture. 
Therefore, this technology allows the quantification of the differences in the 
phosphorylation status of a certain protein. We simultaneously purified Atg9-HTBeaq 
from C12-labeled Atg1 wild type and from C13-labeled atg1∆ cells and analyzed it by on 
line mass spectrometry. Except for the supply of the heavy or light labeled lysines and 
arginines in the media, the two strains were grown without any differences and 
immediately combined after harvesting. To determine the differences between the wild 
type background and the Atg1 deletion background during autophagic conditions, we 
treated both cultures with rapamycin for 45 minutes. Data of four individual experiments 
were combined. We were able to achieve 36% coverage of the peptide sequence of 
Atg9 and at first glance we observed eight sites that show differences between the wild 
type background and the Atg1 deletion background. Figure 5 contains a list of these 
peptides and also displays the extent of their phosphorylation change dependent on 
Atg1.  
 
Site Peptide Atg1wt (13C) : atg1∆ (12C) 
   
S19 NTFLSR no light peptide found 
S802 IAVNGSHTLNSK 100* 
T804 IAVNGSHTLNSK 100* 
S831 MLQSYVYFMDDYSNSENLTGK no light peptide found 
S842 MLQSYVYFMDDYSNSENLTGK 25,4* 
S864 GYNNEGDSFLNNK 3,5 
S948 NDDNNGNNDHEYVLTESFLDSGAFPNHDVIDHNK 66,2* 
S969 MLNSNYNGNGILNK  no light peptide found 
  
 
* peak in elution profile but no isotope pattern 
 
Figure 5. Atg1 dependent sites of Atg9.The presented ratios are the results of the computational analysis. The 
phosphorylation sites shown in black have strong evidence to be directly regulated by Atg1. 
 
For five peptides covering amino acids, namely S804, T804, S842, S864 and S948, 
relative ratios over the light (12C labeled) peptide were determined by quantification 
software (Figure 5), whereas for some phospho-peptides, namely S19, S831, and S969, 
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no ratios have been calculated because no light peptide was found. The absence of the 
light peptide can have two different reasons: first, the light peptide might not have been 
selected from the elution profile for subsequent fragmentation or second, no 
phosphorylated light form exists. The complete lack of a light peptide in the elution 
profile would strongly indicate that this phosphorylated site is directly and exclusively 
regulated by the Atg1 kinase. 
To assure that the phosphorylation status at this site is indeed mediated by Atg1 
and not caused by a technical artifact we reviewed the raw data (together with Verena 
Unterwurzacher) and checked the elution profiles of the peak of the light phospho-
peptides of S19, S831 and S969. Since every peptide is eluted at a specific retention 
time, we compared elution profiles at the correct retention time and specific m/z values 
corresponding to the phospho-peptides in question. Lack of a peak for the 12C labeled 
peptide would be a strong indication for the absence of the corresponding 
phosphorylated peptide in the atg1∆ background. As shown in Figure 6, the 13C elution 
profiles of phospho-peptides S831 as well as of S969 show a suitable peak in the wild 
type sample, however the peak is absent in the atg1∆ sample (12C), which confirms the 







Figure 6. Elution profile of S831 and S969. In the elution profile only a peak for the heavy peptide but not the light is 
found.  
 
Elution profiles of the phospho-peptides covering S802, S842 and at S948 showed a 
possible peak for the atg1∆ (12C) as well as for the wild type (13C) labeled sample. 
These peaks were automatically selected and quantified by the quantification software 
(see Figure 7). However, manual evaluation of the isotope patterns of the light peptides 
showed that the automatically annotated peaks do not have the typical isotope 
distribution. Therefore, our manual validation of the isotope pattern of the MS2 spectra 
suggests that this peak originates from background noise. Therefore, no relative ratios 
for S802, S842 and S948 can be calculated. Thus, phosphorylation at these three sites 







Figure 7. Elution profile and isotope pattern of S802 (A), S948 (B) and S842 (C). A typical isotope pattern (e.g. 
as seen in the heavy isotope pattern of S948) has the highest peak for the peptide containing only the most 
common 12C isotope, the size of the following peak containing a mixture of 12C with the heavier isotope 13C 
decreases with increasing m/z and the peptide that contains only the 13C gives the smallest peak. This figure 
shows that the peak in the elution profile has not the typical isotope pattern that would be seen by a corresponding 
peptide. This gives evidence that the peaks originate from noise.  
 
T804 is located very close to the Atg1 dependent S802. In contrast to S802 which was 
found in several analyses, T804 was only identified in one of the SILAC experiments. 
Therefore, it remains unclear whether this site was identified due to wrong allocation of 
the phosphorylation site or to the variability in the selection of the targeted amino acid 
by the kinase. Moreover, caused by the proximity of the S802 and T804 only one heavy 
peak in the elution profile for both sites can be found (data not shown). Since there is no 
corresponding light peak for T804, this result implicates that also this phosphorylation 
site is absolutely dependent on Atg1. 
The situation is slightly different for the phosphorylation at S19, we observed a 
light peak in the elution profile for phospho-peptide but no heavy to light ratio was not 
calculated by the automated analysis. Manual inspection of the isotope pattern did not 
show the appropriate distribution of the MS2 peaks; therefore the light peak most likely 
does not correspond to the phosphorylated peptide that was identified with the heavy 
peak. Therefore, we believe that the phosphorylation of S19 is also clearly dependent 




Figure 8. Elution profile and Isotope patterns of S831. In the elution profile (left) a light peak that is hard to quantify 
is seen. However, the corresponding isotope pattern does not show a natural distribution.  
 
Taken together, we propose that our SILAC analysis identified at least six definitely 
Atg1 dependent phosphorylation sites on Atg9. Furthermore, we were able to 
corroborate Atg1 dependence of the three phosphorylation sites that have been 
proposed in our initial non quantitative analysis. A fourth phosphorylation site, namely 
S864, which according to our previous analysis was also identified as a putative Atg1 
dependent site, was only found to be moderately dependent on Atg1 with a ratio of 3,5 
(when wild type to an atg1∆ mutant was compared), even if it was strongly induced by 
rapamycin treatment in a wild type strain background. Therefore, we believe that this 
site is also phosphorylated by another kinase, because this site was found to be 
phosphorylated even when the kinase Atg1 is absent. We speculate that this site is 
either targeted by two kinases (an unknown kinase and Atg1) or phosphorylated by an 
unknown kinase that is hyperactivated by Atg1 during autophagic conditions. An 
alternative explanation would be that this phospho-site is regulated by an unknown 
phosphatase which becomes inactivated during autophagic conditions. Furthermore, we 
were able to validate two of the in vitro phospho-sites, namely S831 and S948. 
Proposed kinase defective mutant Atg1K54A still posses kinase activity 
The Atg1K54A mutation has been previously described as kinase defective allele of Atg1 
and has already been used for experiments to gain more insight into the role and 
function of the Atg1 kinase. However, doubts have been raised whether this allele 
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expresses some residual kinase activity (Claudine Kraft, personal communication).  To 
clarify this matter we made use of our established technologies and purified Atg9 from 
the generally used Atg1K54A kinase defective mutant strain background and analyzed 
the phosphorylation pattern via non quantitative analysis. We found phosphorylations at 
two of the sites of Atg9 previously identified as directly dependent on Atg1, namely 
S802 and S969. These findings confirmed our speculation of that this kinase defective 
version still possesses some level of residual kinase activity.  
Characterization of the Atg9-Atg1 interaction via enzymatic tagging 
With our mass spectrometric approach we could show that several Atg9 
phosphorylation sites are directly dependent of Atg1 kinase activity. To validate a direct 
interaction of these two proteins we made use of a protein-protein proximity assay 
based on enzymatic tagging, the so called M-track (I.Dohnal, C.Friedmann and A. 
Zuzuarregui). The M-tack is based on two different tags: first, the catalytic domain of the 
mammalian histone methyltransferase Suv39h1, which serves as donor and was fused 
to Atg9, and second, three repeats of a sequence of the first 21 amino acids of histone 
3, which serves as an acceptor and was fused to Atg1. Interaction of donor and 
acceptor proteins brings the tags into close proximity allowing the transfer of the 
methylgroup onto the histone 3 lysine 9. This modification can be detected by western 
blotting using a specific antibody (see introduction). 
First, we determined interaction dynamics of Atg1 and Atg9 during logarithmic 
growth and after autophagy induction (see Figure 9). 
 
 
Figure 9. M-track detecting the interaction of Atg9 with Atg1 its dynamic. On the left side the blot for the trimethylation  antibody 




We were able to detect a ~126kDa band with a trimethylation antibody. This band 
corresponds to the signal obtained with the HA antibody. Furthermore, the signal fits to 
the size of Atg1 including the 3xH3HA tag. Atg1 alone has a molecular weight of 
101kDa. Furthermore, the trimethylation signal is absent in the Suv negative controls. 
Interestingly, we found that Atg1 and Atg9 strongly interact during logarithmic growth as 
well as at the different time points during autophagy. Since we only observed saturated 
signals the blot does not to provide information about dynamic changes of Atg1 and 
Atg9 interaction. 
To confirm the specificity of the Atg1-Atg9 interaction signal and to exclude the 
possibility that Atg9-Suv unspecifically methylates any histone 3 tagged protein, we 
tested whether Atg9-Suv can methylate Sho1-3xH3HA and Pbs2-Suv interacts with 
Atg1 (see Figure 10). Pbs2 is the MAPKK of the Hog1 MAPK pathway of 
Saccharomyces cerevisiae and Sho1 is a membrane receptor of the Hog1 pathway and 
both factors that are not related to autophagy. The previously established interaction of 
Sho1 and Pbs2 was included as a positive control.  
 
 
Figure  10. M-track  to determine the specificity of an interaction found by Atg9-Suv and Atg1-3xH3HA. Atg1 is not 
methylated by any other Suv tagged protein while Atg9 seems to be able to interact also with other acceptors. 
We observed a strong methylation signal for Sho1-3xH3HA and Pbs2-Suv, which is in 
line with previous studies [A. Zuzuarregui, I. Dohnal and C. Friedmann, PhD thesis]. 
Surprisingly, we observed an interaction signal for Atg9-Suv with Sho1-3xH3HA.  There 
are three explanations for this observation: first, Atg9-Suv can methylate any acceptor 
protein in an unspecific way, or second, Atg9-Suv can easily interact with other 
membrane proteins or membrane associates proteins, because this sort of proteins 
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might share the same compartments during vesicular trafficking, or third, there is a 
connection between autophagy and the Hog1 pathway and Atg9 indeed interacts with 
Sho1 in vivo. 
To test these hypotheses we examined whether Atg9-Suv can methylate other 
acceptor proteins of a pathway that is independent of autophagy (see Figure 11). 
To do so, we used the membrane associated Cdc42-3xH3HA and the 
cytoplasmic Ste20-3xH3HA (both are factors of the Hog1 MAPK pathway). We 
observed no trimethylation signal for an interaction of Atg9 with Ste20 (band size 
including the histone tag would be around ~127kDa) but we could detect a band smear 
in the HA blot. However, Atg9-Suv strongly methylates the membrane associated 
protein Cdc42-3xH3HA (band size of 45kDa). These observations suggest that Atg9-
Suv can lead to signals with membrane proteins, even if the final cellular is different, but 
it still specifically interacts with cytoplasmic proteins. Therefore, we believe that the 
methylation signal obtained with Atg1 represents a true interaction. 
 
 
Figure 11. M-track measuring the interaction of Atg9- Suv with different histone 3 tagged proteins. All five lanes shown 
above originate from the same western blot. The blot for the trimetylation antibody shows a strong interaction for Cdc42, and 
less clear (considering the HA signal) no interaction for Ste20. 
 
Currently, we set up further experiments to confirm the specificity of the Atg1 and Atg9 
interaction. These experiments include the repetition of M-track with Atg1-Atg9, but this 
time with Atg1 containing the methylase tag and Atg9 containing the histone tag. 
Furthermore, we want to test whether the two proteins interact in various deletion 
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backgrounds, which are known to inactivate the kinase and interrupt the assembly of 
the Atg1 complex.  
Mass spectrometric analyses of Atg2 
Similar to the phosphorylation analysis of Atg9, we first used non-quantitative mass 
spectrometry to establish an in vivo phosphomap of Atg2 and to get a first insight into 
the changes of the Atg2 phospho-pattern during logarithmic grow as well as during 
autophagy. Moreover, by examining the Atg2 phospho-pattern in an atg1∆ strain we 
also obtained a first indication for which of the phospho-sites is regulated by the Atg1 
kinase. 
We performed four purifications of Atg2-HTBeaq and achieved a sequence 
coverage of 55,5%, which was evenly distributed throughout the whole protein. Our 
phosphomap of Atg2 contains 14 phosphorylation sites, except one threonine, all of 
them were found at serines. The majority (11 phosphorylations including the phospho-
peptides of S247, S249, S940, S960, S1086, S1113, S1154, S1440, T1450, S1460, 
S1463) was only detected when Atg2 was purified during autophagic conditions. The 
remaining phospho-sites, namely S236, S624 and S954, were found in both conditions 
(see Figure 12). 
Comparing our phopshomaps obtained from wild type background and atg1∆ 
background we achieved an overlapping sequence coverage of 40,3%. All of the 14 
phosphorylations mentioned above were included in the overlapping sequence 
coverage, but only six of the sites, namely S246, S940, S954, S1154, T1450, S1463 
were phosphorylated in the atg1∆ background. However, due to the limited number of 
purifications not all of them can be assumed to be Atg1 dependent. Furthermore, we 
found two additional phosphorylations at Y952 and S1443 in the atg1∆ background; 
both sites were detected during logarithmic growth and during autophagic conditions. 
Because of the high sequence coverage that we obtained with each experiment 




Figure 12. Summary of all phosphorylation analyses of Atg2. The phosphomap in (A) provides an overview of all 
phosphorylation sites of the Atg2 protein sequence, including also previously identified phosphorylations. The exact 




Identification of Atg1 targeted sites in Atg2 via quantitative mass 
spectrometry 
Similar to Atg9, Atg2 was also identified as putative Atg1 target in vitro assays. 
Quantitative analysis of Atg2 phosphorylation sites in vivo found was performed with 
SILAC labeling as described above. We analyzed Atg2, which was purified 
simultaneously from C12-labeled Atg1 wild type background and from C13-labeled atg1∆ 
background; both strains were treated with rapamycin to induce autophagy.  
Despite the fact that the data set is still preliminary (only two individual 
experiments have been integrated so far) the results already provide much information 
due to the high sequence coverage and the repeated identification of most found 
phosphorylation sites. We were able to cover 35,6% of the whole protein sequence of 
Atg2 and confirmed four Atg1 dependent phosphorylations (see Figure 13). 
 
Site Peptide Atg1wt (13C) : ∆atg1 (12C) 
   S249 QAVPDSPVHPFNNDDLSQSVYLSK 22,425 
S940 DIDCDLFNSAFIr no light peptide found 
S1113 NLDGEIQGVQNSFSDVSk 35,559* 
S1086 SNVPQSEANIFDSIYISANk no light peptide found 
      
* peak in elution profile but no isotope pattern 
 
Figure 13. Atg1 dependent sites of Atg2. The presented ratios are the results of the computational analysis. 
 
For phosphorylations on S940 as well as on S1086 no light peptide was identified by the 
quantification software. As described before, these results had to be manually validated 
(together with Verena Unterwurzacher) to assure that a phosphorylated light phospho-
peptide was indeed absent and to exclude the possibility that the phospho-peptide was 
missed by the mass spectrometer. The elution profiles of the phospho-peptides 
containing S940 and S1086 (see Figure 14) show a peak for a 13C labeled peptide but 
not for a 12C labeled peptide.  This absence of a light phosphorylated peptide in the 
atg1∆ background indicates the dependence of the phosphorylation at S940 and S1086 





Figure  14. Elution profiles of S940 and S1086. A peak for the heavy phosphorylated peptides is found in both profiles whereas 
there is no trace of a light phosphorylated form.  
 
For the two other putative Atg1 dependent phosphorylation sites S249 and S1113 a 
ratio was calculated by the quantitation software (see Figure 13). Again, we manually 
validated these ratios. The peak for a phosphorylation site at S1113 was also found in 
the elution profiles of atg1∆ samples in both experiments (data not shown). Similar to 
the phospho-serine 864 of Atg9 this site could be regulated by Atg1 and another kinase. 
However, as shown in Figure 15 the peak of one elution profile had no appropriate 
isotope pattern, whereas the other had at least one isotope pattern that possibly 
corresponds to a light phosphorylated peptide. Taken together, it rather seems more 
likely that there is no phosphorylated peptide in the atg1∆ background. However, for the 
improbable case that the one isotope pattern presents a corresponding light peptide the 
average ratio of the manually integrated peaks would be 66,5. Thus, the 
phosphorylation status of S1113 is regulated by Atg1, but the extent of this regulation 





Figure 15. Isotope patterns for S1113 from two different experiments. On the left no typical pattern can be found 
whereas at least one scan of the 12C peptide shows typical isotope distribution (right).  
 
The peptide containing phospho-serine 249 carries two phosphorylation sites, as shown 
by the two peaks in the elution profile (see Figure 16).  The quantitation of the two 
peaks indicates that the phosphorylation status at S236 is not regulated, while the 
manually integration of peak A gives a ratio of 17,6 and the corresponding isotope 
pattern confirm the correct allocation of the phosphorylation site at S249 (see Figure 
16). Admittedly, in the second experiment only the phosphorylation site at S236 could 
be clearly identified and for the second ambiguously allocated peptide no light peptide 
was found (data not shown). If this second peak belonged to the phosphorylation site on 
S249, this site might be regulated in an Atg1 dependent manner to a higher extent than 
we thought. However, the current data set indicates a role for Atg1 in the regulation of 





Figure 16. Elution profile and Isotope patterns of S249. The light corresponding peak to S249 is heightened in the 
box on the right. Below the both isotope patterns with an appropriate isotope distribution are shown.  
 
Taken together, SILAC analysis enabled the discovery of possible phosphorylation sites 
at S249, S940, S1113, and S1086. Additionally, we could exclude 5 phospho-sites 
(S236, S624, S954, S1154, T1450 and S1463) to be Atg1 dependent that have 
previously been found in the Atg1 wild type background but not the atg1∆ background in 
our non-quantitative analysis. However, due to the size of Atg2 and the low number of 
experiments, more purifications are currently undertaken to obtain a more complete 
picture of Atg2 phosphorylation. 
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Determining a possible interaction between Atg1 and Atg2 - preliminary 
data 
Based on Atg1 dependent phosphorylation sites, which were found via quantitative 
mass spectrometry, we assumed that Atg1 and Atg2 might interact with each other. To 
examine this hypothesis we again used the M-track (described above). We decided to 
fuse Atg2 with the donor tag und Atg1 with the acceptor tag. Producing the read out on 
Atg1, as in the experiments with Atg1 and Atg9, provides us the possibility to compare 
the intensity of the measured interactions. 
To study the interaction dynamics of Atg1 and Atg2 during logarithmic growth and 
during autophagy, we collected samples in a time course experiments; samples were 
taken every 30 minutes from the time points 0 to 2h after treatment with rapamycin. 
 
Figure 17. M-track examining whether Atg1 interacts with Atg2. On the trimethylation blot (left) no band at ~126 
kDa is shown, whereas on the HA-blot appropriate bands are found. In contrast Sho1-3xH3HA gives a strong signal 
for an interaction with Atg2-Suv. 
 
We found a HA-signal at ~126 kDa, but no corresponding trimethylation signal (see 
Figure 17). There are three explanation for this observation: first, there is no interaction 
between Atg1 and Atg2, second, the interaction between these two proteins is too 
transient to trimethylate a histone 3 on lysine 9, so that the trimethylation antibody fails 
to give a signal, or third, the tagging of both proteins on the C-terminus sterically avoids 
an interaction between the donor and acceptor. Interestingly, also the Atg2-Suv (similar 
to Atg9-Suv) gives an interaction signal with the transmembrane protein Sho1-3xH3HA. 
Since Atg2 associates to cellular membranes with the help of Atg18, the signal with 
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Sho1-3xH3HA and the lack of an interaction with the cytoplasmic Atg1 support our 
hypothesis that HMT tagged membrane proteins or membrane associated proteins are 
able to methylate other membrane proteins that are fused with the acceptor tag, but that 
their interaction with cytoplasmic proteins is still specific. 
However, this preliminary data set has to be validated by further experiments 
before an Atg1 and Atg2 interaction can be excluded, especially because we got first 
evidences for a direct connection through the quantitative mass spectrometry. 
Mass spectrometric analysis of Atg18 – preliminary data 
The membrane associated protein Atg18 was the third putative Atg1 target, previously 
identified by in vitro assays. In our Atg1 consensus motif analysis of the yeast genome 
S219 of Atg18 gave the second best hit. However, the point mutation at this site did not 
result in a changed phenotype, therefore we examined whether Atg18 is targeted by 
Atg1 in vivo. Analyses of Atg18 with non-quantitative and quantitative mass 
spectrometry were described as already described for Atg9 and Atg2. The first couple of 
experiments did not provide enlightening information; therefore more intense research is 
required. Our non quantitative analysis revealed only three phosphorylation sites: T383 
and the two unambiguously allocated S201/202 and S382/383 (see Figure 18). The 
phosphorylation sites on S201/202 and T393 were also found in the quantitative 
analysis, but their ratios of 1,3 and 0,9 indicate that these sites are not regulated by the 
kinase Atg1(data not shown). Furthermore, we were able to cover the peptide sequence 
containing S219 in our quantitative as well as in our non-quantitative analysis, but we 
did not detect a phosphorylation of this peptide. This data still has to be extended 




Figure 18. Summary of all phosphorylation analysis of Atg18. The phosphomap in (A) shows all detected 
phosphorylation sites of Atg18. Their exact location is depicted in (B). The green marked regions show the total 
coverage of our analyses. 
Examination of a possibly interaction between Atg1 and Atg18 – 
preliminary data 
So far our mass spectrometric analysis did not show any evidence that Atg18 is 
targeted by Atg1. Therefore, we again decided to use the M-track (described above) to 
confirm Atg18 as target of the kinase Atg1. 
With this assay we examined the interaction of Atg1 and Atg18 during logarithmic 






Figure 19. M-track examining the possibility of an interaction between Atg1 and Atg18. Comparing the absence 
of an Atg1 band on the trimethylation blot (left) with the strong band on the HA-blot (right) there seems to be no 
interaction with Atg18. However, similar to Atg9-Suv and Atg2-Suv, also Atg18-Suv also interacts with the 
transmembrane protein Sho1-3xH3HA. 
 
We obtained a strong HA signal for Atg1, however a lack of a corresponding 
trimethylation signal indicates (similar to Atg2) a weak or no interaction between Atg1 
and Atg18 or that the tags are sterically in the wrong position to interact with each other. 
Similar to the observations of the M-track with Atg2 and Atg9 as donor, also the 
membrane associating Atg18 methylates Sho1-3xH3HA, a further evidence for our 
hypothesis (see Figure 19). Taken together our results suggest that Atg18 is not a 
target of the Atg1 kinase.  
Definition of an Atg1 consensus motif in vivo 
As described above an Atg1 consensus motif has been defined based on in vitro 
assays. This motif has been used in a scan for similar sites on Atg proteins of 
Saccharomyces cerevisiae. Matches have been evaluated according to a so called 
similarity score (defined by scansite). S249 of Atg2 gave a similarity score of 0,3044 (a 
low score indicates high similarity with the motif), which was the best fit that has been 
detected. Moreover, preliminary data obtained by western blotting using a phospho-
specific antibody raised against S249 showed a strong signal that disappeared upon 
phosphatase treatment (Claudine Kraft, unpublished data). These results provided 
further evidence that this site is indeed modified in vivo. Further, studies to examine the 
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dependence of this signal on Atg1 are currently undertaken. However, a serine to 
alanine substitution of this site did not lead to an autophagy relevant phenotype. We 
also identified S249 as Atg1 depended in our quantitative MS analysis. However, a low 
induction ratio (22,4 fold induction during autophagy conditions) as well as the fact that 
S249 was found to be phosphorylated in an atg1∆ background indicates the 
involvement of another kinase or an indirect regulation through Atg1. Our MS analysis 
revealed other sites of Atg2 which better fulfilled the criteria of an Atg1 dependent site. 
For instance, a SILAC experiment comparing wild type to an atg1∆ mutant showed that 
serines 940 and 1086 were not phosphorylated in the Atg1 deletion strain. Compared to 
serine 249 these sites are clearly dependent on Atg1. Moreover, a point mutation of 
S1086 also did not result in an aberrant phenotype. However, we believe that such a 
phenotype might only be expressed when all of these sites are mutated, but 
combinations of point mutations have not been examined yet.  
S219 of Atg18 gave the second best hit (similarity score of 0,334) in the above 
described scan for the Atg1 consensus motif. However, again a point mutation at this 
serine did not show any phenotype. Appropriately, we were not able to detect a 
phosphorylation at S219 in our mass spectrometric analysis, although the peptide 
sequence was covered in most non-quantitative and quantitative runs. Moreover, we did 
not find any other Atg1 dependent site on Atg18 and we were not able to detect an 
interaction signal between Atg1 and Atg18. All in all, the above described results raised 
some doubts whether the in vitro consensus motif is indeed recognized by Atg1 with a 
high affinity in vivo. 
This doubt was further strengthened by the following observation: Serines 657, 
831 and S948 of Atg9 gave higher values and therefore not ideal similarity scores 
(0,7252, 0,6727 and 0,7327). However, phenotypes of single point mutations and 
various combinations of these sites led to an autophagy aberrant phenotype. 
Additionally, we were able to validate S831 and S948 as direct substrates of Atg1 
(unfortunately, we were not to show an Atg1 dependence of S657 due to technical 
difficulties). Additionally, we were able to identify four additional Atg1 regulated sites of 
Atg9, namely S19, S802, S842 and S969. However, similarity scores of this sites would 
indicate no dependence on Atg1 (0,8381, 1,2711, 1,2311 and 0,9260, respectively). 
Again considering the low similarity score that has been determined for some sites that 
have been confirmed in vivo, we believe that a refinement of the Atg1 consensus with 
using our data is necessary. 
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The consensus motif of Atg1 determined by in vitro assays can be defined as follows:  
The phosphorylated amino acid is a serine (hereafter defined with position 0). A 
hydrophobic amino acid (lysine or methionine) on the position -3, a small amino acid at 
position -2, a charged amino acid at position -1 and a hydrophobic amino acid (like 
isoleucine, valine or tyrosine) at positions +1 and/or +2 are preferred. The consensus 
motif obtained by our in vivo analysis possesses some similarity with the above 
described motif. For our analysis we used ten sites on Atg2 and Atg9, which were 
chosen, because they are definitely dependent on Atg1. Similar to the above described 
motif all sites were phosphorylated at a serine. Furthermore, the similarities include a 
preference for a hydrophobic amino acid like lysine or methionine (or valine) at position 
-3 and a tyrosine at position +2. Instead of a small amino acid at position -2 of the in 
vivo consensus motif contains a hydrophobic amino acid like phenylalanine or leucine at 
-2. There is also a lower preference for hydrophobic amino acids at positions +1,+2 and 
+3. Also, the tendency for a charged amino acid at position -1 is lost, except the 







Figure 20. Defining a new Atg1 consensus motif. First row: all Atg1 dependent phosphorylation sites are listed with their similarity 
score that has been calculated by the in vivo consensus (score = 0 means absolute similarity). Below: the new Atg1 consensus 
defined by our in vivo methods is compared to the Atg1 consensus that has been identified by Claudine Kraft with in vitro methods. 
The negative charged amino acids D,E are shown in red, the positive charged N, K, R in blue, the polar  S, T, Y, C and also G in 
green, N,Q in purple and the unpolar uncharged M, L, A, F, I, P, N and V in black. ClustalX and the Weblogo software of Berkeley 
were used to create this Figure. 
 
When looking at the in vivo consensus motif of Atg1 on its own, we detected only a 
preference for a hydrophobic amino acid at positions -3, -2 and partly at +2. However, 
we neglected the possibility of folding effects. Furthermore, some of the in vivo Atg1 
consensus motifs might bind the kinase with stronger affinity than others (therefore the 
consensus sequence might be “attenuated”).  
To address the second problem, we sorted the sequences of our ten sites 
defining the in vivo consensus motif according to their similarity (see Figure 21). The 
sorting was done with the software tool “Distance Matrix” from the ”Mobyle Website”. By 






Figure 21. Atg1 regulated sites sorted by their similarity. Sequences at the top of this alignment have higher 
similarity than the ones at the bottom. The intensity of the coloured amino acids is defined by a conservation visibility 
score of 23. Hydrophobic amino acids are highlighted in reddish colours and hydrophilic amino acids in bluish 
colours. 
 
Using Jalview we highlighted the conserved amino acids of the sorted sequences and 
coloured them according to their hydrophobicity. As shown in Figure 21 the Atg1 
consensus has a strong tendency for hydrophobic amino acids at positions -3 and +2; 
the latter position seems to be less conserved (see lighter staining). Overall the 
sequences would have bad alignment scores (shown in the quality diagram), except for 
positions -3, -2, 0, and +2 (conservation scores between 4-6 and *). This is a further 






Validation of Atg1 dependent phosphorylation sites on target proteins via 
mass spectrometry and protein-protein interaction studies 
The serine/threonine kinase Atg1 has been described to be a key regulator of 
autophagy. Its function and the mechanism of its activation have been thoroughly 
studied, but no reports on target proteins have been published until today. Recently, an 
in vitro and in silico analysis led to the identification of an Atg1 consensus motif. Based 
on sequence similarities with this consensus motif Atg2, Atg9 and Atg18 have been 
identified as putative Atg1 substrates. A study using in vitro kinase assays and point 
mutated variants further strengthened these observations (Claudine Kraft, unpublished 
data and personal communication). To answer the remaining question whether Atg1 
targets this proteins also in vivo and whether it directly interacts with them, we used 
mass spectrometry and a protein proximity assay that was developed in our laboratory. 
We were able to establish a detailed phosphomap of Atg9 including 
phosphorylations found during logarithmic growth as well as during autophagic 
conditions. In total we found 27 phosphorylation sites on Atg9. Furthermore, we 
identified six of these phosphorylations sites (S19, S802, S831, S842, S948 and S969) 
to be regulated by kinase Atg1. Finally, using the M-track we discovered that Atg1 and 
Atg9 do interact during both, rich and autophagic conditions. Therefore, we conclude 
that Atg9 is a direct substrate of Atg1. 
The analysis of Atg2 needs further refinement, but already a number of 
informative results have been obtained with our mass spectrometric analysis. 
Altogether, we were able to map 16 phosphorylations on Atg2 and four of these 
phospho-sites (S249, S940, S1113, and S1086) are regulated by Atg1. Furthermore, we 
detected an absence of a phosphorylation signal at S940 and S1086 in the atg1∆ strain. 
This indicates a direct regulation of these serines by Atg1. Therefore, we strongly 
believe that Atg2 is directly targeted by the kinase. However, we could not observe a 
methylation signal when applying our protein-protein proximity assay. We believe that 
the absence of an interaction signal does not necessarily mean that Atg1 and Atg2 do 
not directly interact. We rather figure that the interaction might not be strong or 
persistent enough for a trimethylation of the acceptor tag or that steric problems such as 
the position of the tags interferes with the generation of the signal even when Atg1 and 
Atg2 interact.  
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Moreover, by establishing the phospho-maps for Atg2 and Atg9 we have found 
many phosphorylations that were only present in autophagic conditions, which indicate 
that additionally to Atg1 also other kinases play a role in the regulation of autophagy. 
Regarding Atg18, our data still has to be considered as incomplete. Our mass 
spectrometric analysis of Atg18 led to the discovery of three phospho-sites, but we were 
not able to detect an Atg1 regulated site amongst them. Appropriately, we were not able 
to detect a trimethylation signal with the M-track. Although, due to the low number of 
purifications for our MS analysis the data of Atg18 are still preliminary, we believe that 
Atg18 is probably not a target of the Atg1.  
 
Figure 22. The impact of our results on the actual model of autophagy. In the initial steps of autophagy the Atg1 
kinase complex, the Atg2-Atg18 complex and Atg9 localize to the PAS (Phagophore Assembly Site). Where Atg1 
commits its kinase activity [11,12]. As our analyses showed the phosphorylated target proteins are Atg2 and Atg9. 
 
The validation of Atg2 and Atg9 as substrates of Atg1 and the identification of the Atg1 
dependent sites on these proteins is only the first step to deepen our understanding of 
the initial steps of autophagy. These results fit well into the actual model of autophagy. 
After receiving the nutrient signal from the TOR pathway, the Atg1 kinase complex 
assembles and localizes to the PAS triggering the PAS localization of other factors and 
complexes like the Vps34 complex, the Atg2-Atg18 complex and Atg9. As suggested by 
Kamada et al. and Kawamata et al. Atg1 possibly commits its kinase activity at the PAS 
[11,12]. Consequently, Atg2 and Atg9 would be phosphorylated after their localization to 
the forming autophagosome. Reggiori et al observed a block in the retrograde transport 
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of Atg9 in Atg1 and Atg2 deletion strains [18]. This would open the question whether the 
Atg1 phosphorylation of Atg2 is also required for the retrograde transport or rather for 
other functions of the Atg2-Atg18 complex. 
Does Atg1 directly interact with its putative targets? 
Additionally to the analysis of the phosphorylation patterns of Atg2, Atg9 and Atg18, this 
work also focused on the validation of a direct interaction of Atg1 with its putative 
targets.  
We received a strong interaction signal for Atg1 with Atg9 during logarithmic 
growth as well as during autophagy. Therefore, we assume that Atg1 directly interacts 
or that the two factors are located in a close proximity. The strong interaction observed 
during logarithmic growth can be caused by basal levels of autophagy activity that can 
always be detected. Alternatively, the interaction could be caused by the Cvt-pathway 
that also requires the assembly of an Atg1 kinase complex. To our knowledge no 
previous studies examined the interaction between these two proteins, but interactions 
of Atg9 with Atg11 and Atg17 have already been described [48,95]. Both, Atg11 and 
Atg17, are components of the active Atg1 kinase complex; Atg11 is required for the Cvt 
pathway and Atg17 for autophagy. This leads to the question whether the interaction of 
Atg1-4xH3HA with Atg9-Suv requires Atg11 and/or Atg17.  
Moreover, to assure the specificity of the interaction signal obtained with Atg9-
Suv and Atg1-4xH3HA, we determined whether Atg9 also gives a trimethylation signal 
with other targets. Surprisingly, we found an interaction signal with Sho1-4xH3HA, a 
component of the (assumingly unrelated) HOG MAPK pathway. We hypothesized that 
Sho1 and Atg9 might cause an artifact methylation signal because they come into close 
proximity as membrane proteins. If so, an interaction signal obtained with cytosolic 
proteins might still be specific. This would mean that Atg9 should not be able to 
methylate other cytosolic proteins; however interactions with other membrane proteins 
might be detectable. Indeed, we could confirm this hypothesis since with our further 
investigations we found an interaction signal of Atg9 with the membrane associated 
protein Cdc42, but no signal with the cytosolic protein Pbs2 (both proteins are also 
components of the HOG MAPK pathway). 
We did not detect any interaction signals between Atg1 with Atg2 or Atg18, but 
based on our mass spectrometric results we believe that at least Atg2 is targeted by 
Atg1. We propose that the improper C-terminal tagging of Atg2 or the transience of the 
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interaction between Atg1 and Atg2 could be likely causes for the failed detection of an 
interaction signal. In the case of Atg18 we were not able to provide any evidence 
supporting its role as an Atg1 substrate, but due to the preliminary state of the data we 
currently cannot exclude the possibility of a connection between Atg18 and Atg1. 
Similar to Atg9, an interaction of Atg1 with Atg2 or Atg18 has not been described, the 
only identified interaction partner of the Atg2-Atg18 complex is Atg9 [18,49]. However, 
to confirm our hypothesis that Atg2 (but not Atg18) is a substrate of Atg1, we have to 
examine whether the exchange of the acceptor with the donor tag, or the tagging of the 
N-terminal ends, or the usage of the mono- or dimethylation antibody give rise to 
interaction signals. 
Atg1K54A defective mutant still possesses some level of activity 
We examined the phosphorylation pattern of Atg9 in the Atg1K54A defective mutant using 
mass spectrometry. The determined phosphorylation pattern included the 
phosphorylations at S802 and S969, which we have previously identified as direct 
substrates of Atg1. Therefore, we conclude that this mutant version of Atg1 still has 
some residual level of kinase activity. Hence, the studies of Kawamata et al. and 
Reggiori et al., who used this kinase defective mutant, have to be carefully interpreted 
[12,18]. For example, the statement of Reggiori et al. which claims that Atg1 kinase 
activity is not required for Atg9 trafficking seems questionable. In contrast, Kawamata et 
al. also used a so called Atg1D211A allele as a second control. This allele is considered to 
be absolutely kinase defective, but it is also uncertain whether the Atg1 kinase complex 
still assembles like in wild type (Claudine Kraft, personal communications). The 
Atg1D211A mutation is located at the beginning of the activation loop [39], whereas 
Atg1K54A is mutated at the ATP binding site (see Uniprot database). Interestingly, for 
both alleles the following observation has been made: Atg1 kinase activity is 
dispensable for the PAS localization of Atg11 and Atg29. Considering the fact that the 
Atg1D211A gives the same results like Atg1K54A also the results also obtained with 
Atg1D211A might possibly need further validation. 
Outlook 
In this work we created a well defined phosphomap of Atg9 including Atg1 dependent 
phosphorylation and established a proximity assay for the further examination of Atg9. 
This makes the investigation of Atg9 or point mutated variants of this protein in different 
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deletion strains and with other proteins possible. Moreover, we can now determine how 
the deletion of components belonging to the Atg1 complex affects the interaction with 
Atg9. For instance, the examination of this interaction in Atg11 and Atg17 deletion 
strains would be interesting since these two proteins were reported to interact with Atg9. 
Thus, the Atg9-Atg1 interaction could be used as readout for the assembly of the Atg1 
complex.  
Similarly, this study provides first insights in the phosphorylation pattern of Atg2. 
Although this data still needs to be extended, it provides information about Atg1 
regulated sites. The analysis of point mutations at these sites would be of great interest. 
We did not receive any signal in the M-track of Atg2 and Atg18, but further refinement of 
the assay can lead to more insights about the role of these two proteins. The 
establishment of the M-track gives us the possibility to examine further putative 
interaction partners and the dynamics of these interactions.  
Confirming Atg2 and Atg9 as targets of Atg1 and identifying the Atg1 regulated 
phospho-sites provides us also the possibility to better characterize the Atg1 kinase 
activity and its effects on Atg2 and Atg9. This could easily be done via fluorescence 
microscopy. Using mutant versions of Atg2 and Atg9 carrying alanine substitutions at 
the Atg1 regulated phospho-sites could reveal whether Atg2 is localized to the PAS 
after or prior to its phosphorylation by Atg1. Moreover, examining the mutant version of 
Atg2 could further clarify whether the Atg1 dependent phosphorylation of Atg2 is directly 
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